A2A Pharmaceuticals

A2A Pharmaceuticals company information, Employees & Contact Information

A2A Pharmaceuticals designs computationally optimized small molecule therapeutics for the treatment of cancer and antibiotic resistant bacterial infections.  Our two oncology programs are focused on inhibiting essential protein-protein interactions in leukemia and in diverse solid tumors. These interactions are critical for cancer progression, but non-essential in normal cells. The antibiotic programs target biosynthetic enzymes in gram-negative bacteria, in pathways not found in humans. The targets selected have no clinically used therapeutics, minimizing susceptibility to resistance; and unlike the numerous follow-on antibiotics currently in development. Our approach integrates interdisciplinary ingenuity with computational tools to design new drug candidates using our proprietary SCULPT platform. Experimentally determined target characteristics guide the selection and placement of fragments to recapitulate key contact points of proteins and/or ligands known to bind. Fragments are incorporated into the target-specific construction of combinatorial in silico libraries, which are designed based on synthetic feasibility. Libraries consisting of thousands to millions of small molecules are iteratively built, and computationally evaluated for potency and optimal ADMET properties. The final selection is made from dozens of iterations, totaling upwards of 100 million compounds.

Company Details

Employees
12
Founded
-
Email
in****@****ons.com
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
Looking for a particular A2A Pharmaceuticals employee's phone or email?

A2a Pharmaceuticals Questions

News

A2A Pharmaceuticals Appoints Dr. Sotirios Stergiopoulos Chief Executive Officer - PR Newswire Canada

A2A Pharmaceuticals Appoints Dr. Sotirios Stergiopoulos Chief Executive Officer PR Newswire Canada

A2A Pharmaceuticals Inc. Today Announced a Multi-target Co-development Agreement With Daewoong Pharmaceutical for AI-enhanced Oncology Drug Discovery - Business Wire

A2A Pharmaceuticals Inc. Today Announced a Multi-target Co-development Agreement With Daewoong Pharmaceutical for AI-enhanced Oncology Drug Discovery Business Wire

Top A2A Pharmaceuticals Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant